Bayer posts 45 percent gain in quarterly earnings

Published On 2019-04-26 03:32 GMT   |   Update On 2019-04-26 03:32 GMT

Bayer said 13,400 plaintiffs were seeking damages, alleging that use of the company's glyphosate-based weedkillers caused their cancer, up from 11,200 in January.


FRANKFURT: German drug and farming supplies company Bayer posted a 45 per cent gain in quarterly core earnings thanks to the acquisition of seed maker Monsanto, while the legal burden it took on with the deal increased.


Adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 4.19 billion euros ($4.67 billion), it said on Thursday, edging past the 4.12 billion euro average analyst forecast in a Reuters poll.


Read Also: Bayer signs deal with adivo to develop antibodies for veterinary medicine


The company said 13,400 plaintiffs were seeking damages, alleging that use of the company's glyphosate-based weedkillers caused their cancer, up from 11,200 in January.


The company is still aiming for an increase in 2019 EBITDA before special items to about 12.2 billion euros, excluding the effect of currency swings and the planned sale of assets such as the animal health unit.


Read Also: Glyphosate Case: Bayer to comply with court mediation order

Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News